Jim Cramer: This Little-Talked-About Drug Could Target the “Biggest Market of All Time” Aside From Eli Lilly's GLP-1 Drugs

Jim Cramer highlighted an Amgen drug that Wall Street has largely ignored, arguing the cardiovascular opportunity could be comparable to the largest-ever pharma market. The piece is bullish on the long-term TAM potential but provides no quantified financial metrics, so near-term market impact is likely limited unless new data or guidance emerges.